Stockscreener 앱 받기
17.31
3.88%
-0.72
Apellis Pharmaceuticals Inc 주식(APLS)의 최신 뉴스
11 Best Guru Stocks to Buy According to Wall Street Analysts - Insider Monkey
Craig Wheeler joins Apellis board, brings biopharma expertise By Investing.com - Investing.com South Africa
RBC Capital Lowers Price Target on Apellis (APLS) Amid Market Survey Insights | APLS Stock News - GuruFocus
Craig Wheeler to Join Apellis Board of Directors - citybiz
Apellis Pharmaceuticals appoints new board member - Investing.com Australia
Apellis Announces Craig Wheeler To Join The Board Of Directors - marketscreener.com
Apellis Pharmaceuticals appoints new board member By Investing.com - Investing.com India
Apellis Pharmaceuticals (APLS) Welcomes Craig Wheeler to Board of Directors | APLS Stock News - GuruFocus
Apellis Announces Craig Wheeler to Join the Board of Directors | APLS Stock News - GuruFocus
Apellis Announces Craig Wheeler to Join the Board of Directors - The Manila Times
RBC Cuts Price Target on Apellis Pharmaceuticals to $21 From $24, Keeps Sector Perform Rating - marketscreener.com
Former Momenta CEO Who Led $13.4B Johnson & Johnson Deal Takes Strategic Role at Apellis - Stock Titan
Apellis Pharmaceuticals (APLS) Target Price Reduced by BofA Ahead of Earnings | APLS Stock News - GuruFocus
BofA Adjusts Price Target on Apellis Pharmaceuticals to $41 From $44, Keeps Buy Rating - marketscreener.com
Geographic Atrophy Therapeutics Market Size in 7MM is expected - openPR.com
Fierce Biotech Layoff Tracker 2025: Mural lays off 90%; Pfizer sells site, cuts staff - Fierce Biotech
The Market Doesn't Like What It Sees From Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Revenues Yet As Shares Tumble 26% - simplywall.st
SHAREHOLDER ALERT: Potential Recovery for Apellis Pharmaceuticals, Inc. (APLS) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Apellis Pharma stock hits 52-week low at $21.66 amid market challenges - Investing.com Canada
Apellis Pharma stock hits 52-week low at $21.66 amid market challenges By Investing.com - Investing.com South Africa
SHAREHOLDER ALERT: Potential Recovery for Apellis Pharmaceuticals, Inc. (APLS) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Raymond James Financial Inc. Purchases New Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Apellis Pharmaceuticals (APLS) - The Globe and Mail
APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag - TradingView
Apellis Looks To Unlock Blockbuster Potential For Empaveli, SyfovreOn A Path To Profitability - RTTNews
Apellis Pharmaceuticals, Inc. (APLS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals - Benzinga
Promising Outlook for Apellis Pharmaceuticals: Buy Rating Backed by Key Milestones and Attractive Valuation - TipRanks
Applis wins FDA review to expand Empaveli label (APLS:NASDAQ) - Seeking Alpha
Apellis Pharmaceuticals Says US FDA Grants Priority Review to Empaveli Application for Rare Kidney Diseases - MarketScreener
Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN - The Manila Times
Breakthrough: EMPAVELI Scores Priority FDA Review After 68% Disease Reduction in Rare Kidney Disorders - Stock Titan
New complement C3 inhibitors disclosed in Apellis patent - BioWorld MedTech
(APLS) Investment Analysis - news.stocktradersdaily.com
Apellis Pharma stock hits 52-week low at $23.77 amid market challenges - Investing.com Australia
Is Apellis Pharmaceuticals, Inc. (APLS) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey
Apellis Pharma stock hits 52-week low at $23.77 amid market challenges By Investing.com - Investing.com South Africa
12 Most Promising Biotech Stocks According to Wall Street Analysts - Insider Monkey
Apellis Pharmaceuticals chief development officer sells shares worth $39,279 - MSN
Interesting APLS Put And Call Options For May 16th - Nasdaq
Morgan Stanley says Fabhalta’s label leaves opportunity for Apellis’ Empaveli - Yahoo Finance
Apellis Pharmaceuticals (APLS) Gets a Hold from Scotiabank - The Globe and Mail
Novartis snags FDA nod for Fabhalta in another kidney disease but leaves room for rival Apellis - Fierce Pharma
Cardurion Taps Apellis Veteran Who Led 450% Team Growth for Top HR Role - StockTitan
1.75%
2.22%
자본화:
|
볼륨(24시간):